Bain Capital Life Sciences
78
111M
48
9.75
16
0.37
22
- Stages of investment
- Areas of investment
Summary
Bain Capital Life Sciences appeared to be the VC, which was created in 2016. The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.
The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Manufacturing, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Annexon Biosciences, Rapid Micro Biosystems, Pharvaris
The overall number of key employees were 2.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Bain Capital Life Sciences, startups are often financed by Correlation Ventures, Omega Funds, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Cormorant Asset Management, Foresite Capital. In the next rounds fund is usually obtained by Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.
The increased amount of exits for fund were in 2018. Considering the real fund results, this VC is 70 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. This Bain Capital Life Sciences works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 78
- Lead investments
- 16
- Exits
- 22
- Rounds per year
- 9.75
- Follow on index
- 0.37
- Investments by industry
- Biotechnology (65)
- Health Care (53)
- Medical (33)
- Pharmaceutical (32)
- Therapeutics (27) Show 13 more
- Investments by region
-
- United States (66)
- South Korea (1)
- Germany (4)
- Netherlands (1)
- Switzerland (3)
- Peak activity year
- 2020
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 5
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 67M
- Group Appearance index
- 0.95
- Avg. company exit year
- 9
- Avg. multiplicator
- 0.88
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Areteia Therapeutics | 12 Jul 2022 | Biotechnology, Health Care, Life Science, Therapeutics | Early Stage Venture | 350M | |
CereVasc | 13 May 2024 | Biotechnology, Health Care, Medical Device | Early Stage Venture | 70M | United States, Massachusetts, Newton |
Mindesk | 30 Jan 2019 | Software, 3D Technology, Real Time, CAD | Seed | 120K | United States, California, San Francisco |
OKP4 | 01 Apr 2022 | Big Data, Cryptocurrency, IT Infrastructure, Blockchain | Seed | Midi-Pyrenees, Toulouse, France |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.